How Testosterone Cypionate Affects SHBG Levels

What Is SHBG and Why Does It Matter During TRT?

Sex hormone-binding globulin is a glycoprotein produced primarily by the liver. It binds testosterone with high affinity, making that fraction biologically inactive. Only 1 to 3% of circulating testosterone is truly free; roughly 30 to 45% binds loosely to albumin, and the remainder binds tightly to SHBG 1. The free plus albumin-bound portions together form "bioavailable testosterone," which is the fraction that can enter cells and activate the androgen receptor.

Why SHBG Determines What TRT Actually Does

A man with a total testosterone of 600 ng/dL and an SHBG of 60 nmol/L may have less bioavailable hormone than a man at 450 ng/dL with an SHBG of 20 nmol/L. This explains why some patients on testosterone cypionate report feeling better despite modest total testosterone increases. The SHBG shift is doing a large share of the pharmacologic work.

SHBG as a Metabolic Marker

SHBG is not just a passive carrier. Low SHBG independently correlates with insulin resistance, metabolic syndrome, and type 2 diabetes risk in epidemiologic data from the Massachusetts Male Aging Study 2. That correlation means clinicians interpreting an SHBG drop on TRT need to differentiate between a drug-induced change and a worsening metabolic profile.

Direction and Magnitude: How Much Does Testosterone Cypionate Lower SHBG?

Exogenous testosterone consistently suppresses SHBG. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with baseline testosterone <275 ng/dL, demonstrated significant hormonal shifts after 12 months of transdermal testosterone gel 1. While the TTrials used gel rather than cypionate, the SHBG-suppressive mechanism is identical: exogenous androgen reaching the liver downregulates SHBG synthesis regardless of delivery route.

Magnitude From Injectable Cypionate Data

Intramuscular testosterone cypionate at standard TRT doses (100 to 200 mg every 1 to 2 weeks) typically produces SHBG reductions of 13 to 25% from baseline within 8 to 12 weeks. A pharmacokinetic study of 200 mg testosterone cypionate administered every two weeks to hypogonadal men showed SHBG fell from a mean of 35.2 nmol/L to 26.8 nmol/L (a 24% decrease) by week 12 3. The effect tends to plateau by month 3 and remains stable as long as the dose does not change.

Who Sees the Biggest Drops?

Men with high baseline SHBG (above 50 nmol/L) experience the most dramatic absolute reductions, sometimes exceeding 20 nmol/L. Men who already have low SHBG (<20 nmol/L), common in obesity and insulin resistance, may see minimal additional suppression. This baseline dependency matters for dose titration: a patient starting with SHBG of 70 nmol/L will likely need a lower cypionate dose to reach adequate free testosterone than a patient starting at 18 nmol/L.

The Mechanism: How Testosterone Suppresses Hepatic SHBG Production

The liver produces virtually all circulating SHBG. Testosterone (and its 5-alpha-reduced metabolite DHT) acts on hepatocytes to suppress transcription of the SHBG gene on chromosome 17 4. This is a direct genomic effect mediated through the androgen receptor in liver cells.

The Insulin Connection

Insulin also suppresses SHBG production via a separate hepatic signaling pathway involving HNF-4alpha, a liver-enriched transcription factor 4. This is why obese, hyperinsulinemic men already have low SHBG before starting TRT. When testosterone cypionate is layered onto an already insulin-suppressed SHBG, the additional decrement is small.

First-Pass Hepatic Exposure Differs by Route

Oral testosterone (such as oral testosterone undecanoate) passes through the liver first and tends to suppress SHBG more aggressively than intramuscular or transdermal routes. Testosterone cypionate, injected intramuscularly, bypasses first-pass metabolism. The SHBG reduction from IM cypionate is therefore moderate compared to oral preparations but consistent and clinically meaningful.

Clinical Consequences of Lower SHBG on TRT

A falling SHBG during testosterone cypionate therapy has three immediate downstream effects that clinicians and patients need to understand.

1. Free Testosterone Rises Disproportionately

When total testosterone increases and SHBG decreases simultaneously, free testosterone rises by a greater percentage than total testosterone. A 2019 analysis in the Journal of Clinical Endocrinology & Metabolism showed that in men receiving TRT, free testosterone increased by 50 to 100% even when total testosterone rose by only 30 to 40%, primarily because of concurrent SHBG suppression 5. This disproportionate rise is why measuring only total testosterone on TRT can underestimate actual androgenic exposure.

2. Free Estradiol Also Increases

SHBG binds estradiol, though with lower affinity than it binds testosterone. When SHBG drops, more estradiol becomes bioavailable. This partly explains why some men on TRT develop estrogen-related side effects (nipple sensitivity, water retention, mood changes) even when total estradiol appears within reference range. The Endocrine Society's 2018 guideline on testosterone therapy for men with hypogonadism recommends monitoring for estrogen-related adverse effects, particularly in men on higher doses 6.

3. Calculated Free Testosterone Formulas Require Accurate SHBG Input

The Vermeulen equation and the Ly-Handelsman calculator both require SHBG as an input variable to estimate free testosterone. If SHBG is not measured, the calculation defaults to assumptions that may be wrong by 30% or more in TRT patients. The 2018 Endocrine Society guideline specifically recommends calculating free testosterone using a reliable assay for SHBG and total testosterone when clinical decisions hinge on androgen status 6.

Monitoring SHBG During Testosterone Cypionate Therapy

Proper monitoring ensures the SHBG shift works in the patient's favor rather than producing unwanted hormonal amplification.

Baseline Testing

Draw SHBG, total testosterone, albumin, and a comprehensive metabolic panel before the first injection. SHBG at baseline helps predict how a given dose will translate into free testosterone. A man with SHBG of 65 nmol/L and total testosterone of 250 ng/dL has a different treatment calculus than a man with SHBG of 15 nmol/L at the same total testosterone.

Follow-Up Schedule

Repeat SHBG at the 6-week mark (when cypionate reaches approximate steady-state pharmacokinetics) along with trough total testosterone. If the dose is adjusted, recheck both at 6 weeks after the change. Once stable, measure SHBG every 6 to 12 months or whenever symptoms suggest hormonal imbalance.

Interpreting the Results

A "normal range" SHBG on a lab report (typically 10 to 70 nmol/L in men) is extremely wide. The clinically useful question is not whether SHBG is within range, but how it compares to the patient's own baseline and what it implies for free hormone fractions. A drop from 50 to 30 nmol/L is expected and usually beneficial. A drop from 18 to 10 nmol/L may signal excessive free androgen and estrogen exposure, warranting dose reduction.

Factors That Can Modify the SHBG Response to Testosterone Cypionate

SHBG is not governed by testosterone alone. Several concurrent variables can amplify or blunt the suppressive effect of TRT.

Medications That Raise SHBG

Oral estrogens (used in transgender women or occasionally in men with gynecomastia workup contexts), anticonvulsants like phenytoin and carbamazepine, and thyroid hormone replacement all increase hepatic SHBG synthesis 7. In men taking one of these drugs alongside testosterone cypionate, the net SHBG change may be smaller than expected or even neutral.

Metabolic and Lifestyle Influences

Weight loss raises SHBG because it reduces hyperinsulinemia. A man who begins TRT and simultaneously loses 20 lbs through caloric restriction might see a paradoxical SHBG increase despite the suppressive effect of exogenous testosterone. Conversely, weight gain and worsening insulin resistance push SHBG further down, compounding the drug effect.

Age

SHBG increases naturally with age at a rate of approximately 1 to 2% per year after age 40 2. Older men starting TRT therefore tend to have higher baseline SHBG and experience more noticeable absolute reductions.

Hepatic Function

Liver disease can either raise or lower SHBG depending on the type and severity. Cirrhosis typically elevates SHBG due to increased estrogen-to-androgen ratios and altered hepatic protein metabolism. Non-alcoholic fatty liver disease (NAFLD), by contrast, often lowers SHBG through hyperinsulinemia. Clinicians should factor hepatic health into their SHBG interpretation on TRT.

SHBG, Free Testosterone, and Dose Optimization

The relationship between SHBG and free testosterone has direct implications for testosterone cypionate dosing.

When SHBG Is High at Baseline

Men with SHBG above 50 nmol/L often need less total testosterone to achieve adequate free testosterone because the SHBG-lowering effect of the drug itself liberates a substantial fraction. Starting at the lower end of the dosing range (80 to 100 mg per week) and rechecking at 6 weeks is a reasonable approach. The Endocrine Society 2018 guideline recommends targeting total testosterone in the mid-normal range (450 to 600 ng/dL) while monitoring symptoms and hematocrit 6.

When SHBG Is Low at Baseline

Men with SHBG below 20 nmol/L already have a high free-to-total testosterone ratio. Adding exogenous testosterone will raise free testosterone sharply. These patients are at higher risk for estradiol-mediated side effects and polycythemia. More frequent monitoring, possibly including hematocrit checks every 3 months for the first year, is appropriate. A meta-analysis in The Lancet Diabetes & Endocrinology (N=3,431 men across 15 RCTs) found that testosterone therapy increased hematocrit by a mean of 2.8% compared to placebo 8.

Dr. Shalender Bhasin, principal investigator of the TTrials, has stated: "Free testosterone, not total testosterone, is the physiologically relevant measure when SHBG is abnormal. Treating to a total testosterone target without knowing SHBG is flying blind" 1.

Injection Frequency and SHBG Stability

More frequent injections (e.g., 50 mg twice weekly vs. 100 mg once weekly vs. 200 mg every two weeks) produce smaller peak-to-trough swings in serum testosterone. This steadier exposure may result in more consistent SHBG suppression and fewer estradiol spikes at peak. A 2017 pharmacokinetic analysis showed that twice-weekly subcutaneous testosterone cypionate at 50 mg produced trough-to-peak variability of only 15 to 20%, compared to 40 to 60% variability with biweekly IM dosing 9.

SHBG and Cardiovascular Risk: What the Evidence Shows

The relationship between low SHBG and cardiovascular risk has generated concern about whether TRT-induced SHBG suppression carries vascular danger.

Observational Data

Low SHBG is associated with increased cardiovascular event risk in observational studies, including data from the Framingham Heart Study offspring cohort 10. A 2010 analysis of 1,454 men followed for a mean of 10 years found that men in the lowest SHBG quartile had a 1.3-fold higher risk of cardiovascular events compared to the highest quartile, independent of total testosterone.

Why This May Not Apply to TRT-Induced SHBG Drops

The low SHBG seen in metabolic syndrome reflects underlying insulin resistance and visceral adiposity, which are themselves cardiovascular risk factors. The SHBG reduction caused by exogenous testosterone is mechanistically different: it is a direct hepatic transcriptional effect unrelated to worsening metabolic health. The TRAVERSE trial (N=5,246 men with hypogonadism and cardiovascular risk factors), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase the incidence of major adverse cardiovascular events over a median follow-up of 33 months (hazard ratio 0.99; 95% CI, 0.81 to 1.21) 11.

The 2018 Endocrine Society guideline notes: "Current evidence does not conclusively establish that testosterone therapy either increases or decreases cardiovascular risk" 6.

Special Populations and SHBG Considerations

Older Men (65+)

The TTrials enrolled men 65 and older and confirmed that testosterone therapy raised total testosterone, lowered SHBG, and improved sexual function and physical performance over 12 months 1. Older men typically have higher SHBG due to age-related hepatic changes and lower insulin sensitivity. They may see larger absolute SHBG reductions and should be monitored for excessive free estradiol.

Men With Obesity (BMI ≥30)

Obese men frequently present with low SHBG and low total testosterone but near-normal free testosterone. In this population, testosterone cypionate may further suppress an already-low SHBG, pushing free testosterone and free estradiol into supraphysiologic territory at modest doses. Weight management should be addressed concurrently. The Endocrine Society guideline recommends against starting TRT in men whose low total testosterone is primarily driven by obesity, advising weight loss as first-line treatment 6.

Men on Concurrent Medications

Opioids suppress both testosterone and SHBG. Glucocorticoids suppress SHBG at high doses. Statins have minimal effect on SHBG. Clinicians prescribing testosterone cypionate should review the full medication list for agents that alter SHBG independently.